Borazan Ali, Ustün Hasan, Ustundag Yucel, Aydemir Selim, Bayraktaroglu Taner, Sert Mehmet, Yilmaz Ahmet
Department of Internal Medicine, Zonguldak Karaelmas University, Faculty of Medicine, Zonguldak, Turkey.
Mediators Inflamm. 2004 Jun;13(3):201-4. doi: 10.1080/09511920410001713493.
Markers of an acute phase reaction, such as C-reactive protein (CRP) or tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6, are predictive for cardiovascular morbidity and mortality in normal subjects and in chronic renal failure patients. In this study, we aimed to investigate serum TNF-alpha, IL-6, IL-10 and CRP levels in continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) patients.
Serum levels of TNF-alpha, IL-6, IL-10 and CRP levels were measured in 30 patients who were just diagnosed with end-stage renal failure and treated, with 16 CAPD (nine female, seven male) and 14 HD (eight female, six male) patients, before CAPD or HD treatment and after 3 months from the beginning of CAPD or HD in patients with no clinical signs of infection. The control groups were 20 healthy persons of similar age and sex. Serum levels of TNF-alpha, IL-6, IL-10 and CRP were measured by enzyme-linked immunosorbent assay in stable CAPD and HD patients and in healthy persons.
The mean serum levels of TNF-alpha, IL-6, IL-10 and CRP showed no significant differences between the CAPD and HD patients for the beginning values and the third month of treatment. However, serum TNF-alpha, IL-6, IL-10 and CRP levels were higher than the control group in the CAPD and HD patients regarding the beginning values and the third month of treatment (p < 0.001).
CAPD and HD of the renal replacement therapy have no effects on serum CRP and cytokines.
急性期反应标志物,如C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)和白细胞介素(IL)-6,可预测正常人和慢性肾衰竭患者的心血管发病率和死亡率。在本研究中,我们旨在调查持续性非卧床腹膜透析(CAPD)和血液透析(HD)患者的血清TNF-α、IL-6、IL-10和CRP水平。
对30例刚被诊断为终末期肾衰竭并接受治疗的患者进行血清TNF-α、IL-6、IL-10和CRP水平检测,其中16例CAPD患者(9例女性,7例男性)和14例HD患者(8例女性,6例男性),在CAPD或HD治疗前以及开始CAPD或HD治疗3个月后(无感染临床症状的患者)。对照组为20名年龄和性别相似的健康人。采用酶联免疫吸附测定法测量稳定期CAPD和HD患者以及健康人的血清TNF-α、IL-6、IL-10和CRP水平。
CAPD和HD患者治疗开始时和第三个月的血清TNF-α、IL-6、IL-10和CRP平均水平无显著差异。然而,CAPD和HD患者治疗开始时和第三个月的血清TNF-α、IL-6、IL-10和CRP水平高于对照组(p < 0.001)。
肾脏替代治疗中的CAPD和HD对血清CRP和细胞因子无影响。